Bank of America Securities Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Intellia Therapeutics, with a price target of $17.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Moderna, and Crispr Therapeutics AG. According to TipRanks, Stranahan has an average return of 4.0% and a 52.37% success rate on recommended stocks.

In addition to Bank of America Securities, Intellia Therapeutics also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued today. However, yesterday, TD Cowen maintained a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).

Based on Intellia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $95.79 million. In comparison, last year the company earned a revenue of $12.87 million and had a GAAP net loss of $128.9 million

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year. Last month, JAMES BASTA, the EVP & GC of NTLA sold 10,397.00 shares for a total of $95,756.37.